Subcutaneous engineered factor VIIa marzeptacog alfaactivated n hemophilia with inhibitorsPhase 2 trial of pharmacokinetics pharmacodynamics efficacy and safety

Johnny MahlanguHoward LevyMarina KosinovaHeghine KhachatryanBartosz Korczowski2023-04-132023-04-13DOAJ2475-0379https://hdl.handle.net/10539/35000Subcutaneous engineered factor VIIa marzeptacog alfaactivated n hemophilia with inhibitorsPhase 2 trial of pharmacokinetics pharmacodynamics efficacy and safety